Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;17(11):45-49.

Young Psoriatic Patients Respond Faster to Dimethyl Fumarate: Age-related Differences in Efficacy and Adverse Events

Martina Burlando  1 , Adelaide Algeri  1 , Ilaria Salvi  1 , Emanuele Cozzani  1 , Aurora Parodi  1
Affiliations

Young Psoriatic Patients Respond Faster to Dimethyl Fumarate: Age-related Differences in Efficacy and Adverse Events

Martina Burlando et al. J Clin Aesthet Dermatol. 2024 Nov.

Abstract

Background: Dimethyl fumarate (DMF) is an oral treatment approved by the European Medicines Agency (EMA) to treat moderate-to-severe plaque psoriasis among adult patients.

Objectives: This study aims to evaluate sociodemographic, anthropometric, and medical characteristics in patients with psoriasis without previous history of traditional systemic therapy and to observe if the efficacy or AEs of dimethyl fumarate correlate to any of the patients' characteristics.

Methods: Ninety-two patients with mild-to-moderate psoriasis were enrolled. Each patient was reviewed at 4, 12, 24 and 36 weeks. The PASI score and any clinical side effects or blood count abnormalities were recorded.

Results: After 4 weeks, a decrease in the median value of PASI index was already noticeable (p<0.001). After 12 weeks of treatment, 43.9% of patients reached PASI-50, 12.3% PASI-75. The patients achieving PASI-75 after 12 weeks of treatment were significantly younger than those who did not. Age, BMI index, gender and gastroprotection used were not significantly related to the occurrence of side effects.

Conclusion: Profiling of patients could be useful in predicting the response to treatment. In our study, younger patients were found to respond better to dimethyl fumarate.

Keywords: adverse events, psoriasis; age; dimethyl fumarate; efficacy.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES: Drs. Burlando and Parodi have served as speakers for AbbVie, Amgen, Almirall, Eli Lilly, Janssen, Novartis, and UCB.

Figures

FIGURE 1.
FIGURE 1.
Comorbidities
FIGURE 2.
FIGURE 2.
Concomitant therapies
FIGURE 3.
FIGURE 3.
PASI score at each visit
FIGURE 4.
FIGURE 4.
Age and PASI index after 12 weeks
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mrowietz U, Barker J, Boehncke WH et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol. 2018;32(Suppl 3):3–14. - PubMed
    1. Carboni I, De Felice C, De Simoni I et al. Fumaric acid esters in the treatment of Psoriasis: an Italian experience. J Dermatolog Treat. 2004;15(1):23–26. - PubMed
    1. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol. 2004;150(4):741–746. - PubMed
    1. Heelan K, Markham T. Fumaric acid esters as a suitable first-line treatment for severe psoriasis: an Irish experience. Clin Exp Dermatol. 2012;37(7):793–795. - PubMed
    1. Pezzolo E, Cazzaniga S, Di Leo S et al. Efficacy and safety of dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real-world clinical experience. J Eur Acad Dermatol Venereol. 2022;36(7):e534–e537. - PubMed

LinkOut - more resources